Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Directly administered antiretroviral therapy Clear all
Completed Not applicable Interventional

Directly Observed Therapy for Community-Released HIV+ Prisoners

NCT00786396
View directory record Official record
Conditions
HIV/AIDS, Substance Abuse
Interventions
Directly administered antiretroviral therapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2Phase 3 Interventional

Directly Administered HIV Therapy in Methadone Clinics

NCT00279110
View directory record Official record
Conditions
HIV Infections, Heroin Dependence
Interventions
Directly administered antiretroviral therapy (DAART)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

NCT00036452
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
27
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 28, 2026, 10:13 AM EDT
Withdrawn Phase 1 Interventional

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

NCT05079451
View directory record Official record
Conditions
HIV Infections
Interventions
3BNC117-LS, 10-1074-LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

NCT03048422
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Directly Observed Antiretroviral Therapy Among Active Drug Users

NCT00367172
View directory record Official record
Conditions
HIV/AIDS, Substance Abuse
Interventions
Directly Administered Antiretroviral Therapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 28, 2026, 10:13 AM EDT